The differences of clinical characteristics and outcomes between imported and local patients of COVID-19 in Hunan: A two-center retrospective study

Chang Wang
the second xiangya hospital, Central South University

Lizhi Zhou
Central South University Xiangya School of Medicine

Juan Chen
the central hospital of Xiangtan

Yong Yang
the central hospital of Changsha

Tianlong Huang
the second xiangya hospital, CSU

Min Fu
the forth hospital of Changsha

Ya Li
the second Xiangya hospital, CSU.

Daniel George
Royal Adelaide Hospital

Xiangyu Chen (✉ chenxiangyu@csu.edu.cn)

Research

Keywords: COVID-19, SARS-CoV-2, clinical characteristics, outcomes, virulence

DOI: https://doi.org/10.21203/rs.3.rs-23247/v2

License: ☒ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** The clinical characteristics and outcomes of the 2019 novel coronavirus (COVID-19) pneumonia are different in Hubei compared to other regions in China. But there are few comparative studies on the differences between imported and local patients which may provide information of the different courses of the virus after transmission.

**Methods:** We investigated 169 cases of COVID-19 pneumonia in two centers in Hunan Province, and divided them into two groups according to epidemiological history, "imported patients" refers to patient with a clear history of travel in Wuhan within 14 days before onset, and "local patients" refers to local resident without a recent history of travel in Wuhan, aiming to analyze the difference in clinical characteristics and outcomes between the two groups. All the epidemiological, clinical, imaging, and laboratory data were analyzed and contrasted.

**Results:** The incidence of fever on admission in imported patients was significantly higher than local patients. There was a significantly higher proportion of abnormal pulmonary signs, hypokalemia, hyponatremia, prolonged PT, elevated D-dimer and elevated blood glucose in imported patients. Compared with local patients, the proportion using antibiotics, glucocorticoids and gamma globulin were significantly higher in imported patients. The moderate type was more common in local patients, and the severe type were more frequent in imported patients. In addition, the median duration of viral clearance was longer in imported patients.

**Conclusions:** In summary, we found that imported cases were more likely to develop into severe cases, compared with local patients and required more powerful treatments.

**Trial registration:** Registered 21st March 2020, and this study has been approved by the Medical Ethics Committee (Approved Number. 20200017).

**Background**

The outbreak of COVID-19 pneumonia was recognized in December 2019 and the World Health Organization declared 2019-nCoV epidemic as a Public Health Emergency of International Concern on January 30th, 2020 [1]. As of June 15th, 2020, China has confirmed 84,778 patients and 4,645 deaths [2]. Among them, 1,019 patients were confirmed, and four patients died in Hunan [3]. The pathogen that caused the outbreak now is officially named SARS-CoV-2, which is a member of the coronavirus family [4].

Compared with the studies in Wuhan and other provinces and cities in China, we found that Wuhan has a higher rate of severe patients, higher mortality, and longer hospitalization time [5-7]. Previous studies suggest that most viruses will co-evolve with their hosts, and intermediate virulence maximizes pathogen fitness, which is a trade-off between virulence and transmission [8]. Excluding the influence of environmental factors, has the virulence of the SARS-CoV-2 been reduced in the process of transmission?
Regretfully, few studies focus on this area at present, which is conducive to our comprehensive understanding of the clinical and epidemiological characteristics of COVID-19.

Hunan is geographically adjacent to Hubei, and many people have escaped into Hunan before Wuhan closed the city borders [9], which may lead to many potentially infected patients. Since it is relatively difficult to distinguish the generations of patients clinically, we adopted two classifications: “imported patients” refers to patients with a clear history of travel in Wuhan within 14-days before onset, while “local patients” refers to local residents without a recent history of travel in Wuhan.

In this study, we collected data from 169 adult COVID-19 pneumonia patients from two centers in Hunan Province. All patients were divided into imported patients and local patients according to epidemiology history. We made a comprehensive comparison and analysis of their clinical features and outcomes to explore the differences between the two groups.

**Methods**

**Study Design and Participants**

This is a two-center, retrospective study. We enrolled 169 adult patients of COVID-19 pneumonia admitted to hospital in Changsha and Xiangtan, Hunan Province from January 21\textsuperscript{st}, 2020 to February 21\textsuperscript{st}, 2020. Examining the physiological differences between children and adults, however, the differences in clinical characteristics between children and adult cases of COVID-19 pneumonia patients has been confirmed [10], we therefore abandoned the inclusion of underage patients. The enrolled patients included 134 patients from Changsha Public Health Treatment Center and 35 patients from Xiangtan Central Hospital. Both hospitals are the only designated hospitals to treat COVID-19 pneumonia patients in Changsha and Xiangtan respectively. All patients were diagnosed as COVID-19 pneumonia according to the guidelines issued by the National Health Commission of the People's Republic of China (PRC) [11] and divided into imported patients (74 patients) and local patients (95 patients) according to their epidemiological history. All the clinical data was collected separately up to March 2\textsuperscript{nd}, 2020.

**Procedures**

All patients were diagnosed according to the guidelines of the National Health Commission of the PRC [11], all suspected patients were tested with nasal/pharyngeal swabs by reverse transcription polymerase chain reaction (RT-PCR) immediately. If the nucleic acid test was positive, patients would be registered as confirmed.

We collected the basic information (gender, age, epidemiological history, underlying diseases, etc.), clinical characteristics and signs (fever, respiratory symptoms, gastrointestinal symptoms, respiratory frequency, fatigue, etc.), laboratory data (blood biochemistry, coagulation function, blood gas analysis, liver and kidney function assessment, infection-related biomarkers, etc.), imaging results (ground-glass opacity, consolidation, involved scope, pleural effusion, etc.), and treatment measures (respiratory
support, antiviral drugs, antibiotics, hormones, etc.), from the hospital medical records. The data were as of March 2nd, 2020. If important data was missing or clarification was needed, we obtained the data by communicating with the attending clinicians. For imaging data, we used two commercial multi-detector CT scanners (LightSpeed, GE Medical Systems, USA; SOMATOM, Siemens Medical, Germany) to perform chest CT scans in all patients. CT images were collected during one or two breath holds. Imaging features include the type and distribution of lesions, the number of lesions and the lobes involved. All CT images were read by two radiologists with more than 10 years' experience, and if differences arose, a third radiologist was added for analysis.

Before the data was collected, the attending clinicians had classified all patients into four categories: mild, moderate, severe and critical types, according to the guidelines of the National Health Commission of the PRC [11]. We followed the attending clinicians' classification.

Outcomes

The primary outcome was death. The secondary outcomes included the incidence of serious complications, utilization rate of mechanical ventilation and the duration to negative RT-PCR tests.

Definitions

Fever is defined as the temperature equal or higher than 37.3°C, slight fever is 37.3-38.0°C, and high fever is >39.0°C. Anemia is defined as hemoglobin lower than 120g/l. Hypoalbuminemia is the level of albumin lower than 40.0g/L. The level of serum sodium lower than 135mmol/L is defined as hyponatremia.

Oxygen therapy: Including nasal cannula oxygen therapy, high-flow nasal cannula oxygen therapy, non-invasive positive pressure ventilation and invasive positive pressure ventilation. All the patients were administered oxygen therapy, except the patients did not accept. The indication for setting up extracorporeal membrane oxygenation (ECMO): patient with invasive positive pressure ventilation, (1) with a FiO2>90%, the oxygenation index is less than 80mmHg, lasts for more than 3-4 hours; (2) airway platform pressure $\geq 35\text{cmH}_2\text{O}$ [11].

Confirmed standard [11]:

a. Nasal / Pharyngeal swabs or other samples were positive for viral nucleic acid tested by RT-PCR,

b. The gene sequencing of the virus was highly homologous to the known novel coronavirus 2019.

Clinical classification standard [11]:

c. Mild: Clinical symptoms are slight, with no pneumonia manifestations seen on imaging,

d. Moderate type: With symptoms such as fever and difficulty breathing, with pneumonia manifestations seen on imaging,
e. Severe: Shortness of breath, RR>30 beats/min, or oxygen saturation <93% at rest, or arterial blood oxygen partial pressure (PaO₂)/oxygen concentration (FiO₂) <300mmHg, or lung imaging demonstrating lesion progression more than 50% within 24-48 hours,

f. Critical: Respiratory failure requiring mechanical ventilation, or shock, or multiple organ failure requiring ICU monitoring and treatment.

**Statistical analysis**

For continuous variables, we expressed them as a mean with standard deviation (SD) or median with interquartile range (IQR). We assessed the differences by two-sample T-test or Mann-Whitney test. Categorical variables were expressed as counts (%), and differences were tested by χ² or Fisher exact tests, if appropriate. For the laboratory results, we also evaluated whether the values were beyond the normal range. We used SPSS (version 26.0) for all analyses, p<0.1 was considered statistically significant, due to the small sample size.

**Results**

**Demographics, baseline and clinical characteristics of COVID-19 pneumonia patients (table 1)**

In our study, 74 (43.7%) patients had a clear history of living in Wuhan before the onset of the disease, including Wuhan locals and those working, studying, or traveling in Wuhan. These patients who were infected with the virus in Wuhan were regarded as imported patients, while the rest were regarded as local Hunan patients. There were no medical staff in our patient population.

The median age of all patients was 45-years (IQR 34.5 to 55). The median age of imported patients was 45-years, and local patients was 43-years. The age of the patients was mainly between 19 and 49-years (67.6% of imported patients and 58.9% of local patients). The proportion of local patients over 50-years old (41%) was slightly higher than that of imported patients (32.5%). There was no significant difference in gender between the two groups. The male-to-female ratio of all patients was close to 1:1, which was consistent with the study of Wu et al. [12].

On admission, the body temperature for most patients was below 37.3 °C. Among the fevers, most of them were considered slight fevers, and only 1 case had a high fever. The incidence of fever in imported patients (37.9%) was significantly higher than that in local patients (22.1%, p=0.065).

The abnormal physical signs on pulmonary auscultation were largely crackles or mixed crackles and stridor. The proportion of abnormal pulmonary signs was significantly higher in imported patients (10.9% vs 4.2%). Only three of the imported patients had mixed crackles and stridor compared with none of the local patients.

Among all the patients, 31.4% had at least one comorbidity. Compared with local patients, imported patients had a higher proportion of underling comorbidities (35.8% vs 25.7%), no statistical significance
was found. The top three comorbidities were hypertension (8.1% vs 13.7%), diabetes (5.4% vs 9.5%), and cardiovascular and cerebrovascular diseases (2.7% vs 8.4%) in each group.

In this study, cough (86.5% vs 75.8%), fever (78.4% vs 68.4%) and fatigue (both 43.2%) were still the three most common clinical symptoms of COVID-19 pneumonia in both groups. However, the proportion of gastrointestinal symptoms (such as nausea, vomiting, diarrhea, etc.) was also close to one third (29.7% vs 32.6%), which is not as low as the previous study [7]. However, no statistical significance was observed between the two groups. In addition, the median symptom onset-visit interval of both imported and local patients was 3-days, with no significant difference.

**Radiographic findings of COVID-19 patients (table 2)**

On admission, radiographs demonstrated that 130 of the 166 patients (78.3% vs 78.1%) had ground-glass opacity (GGO), and 21 of the 166 patients (13.7% vs 11.8%) had mixed GGO and consolidation. One patient had consolidation only. The proportion of bilateral pneumonia was higher in imported patients (84.9% vs 79.6%) while the proportion of unilateral pneumonia was higher in local patients (8.2% vs 14.0%). However, no significant difference was observed.

When treated for 5-7 days after admission, the proportion of patients with only GGO decreased (54.2% vs 46.2%), while the proportion of mixed GGO and consolidation patients increased (29.2% vs 35.2%) in both groups, which conforms to the natural variation of lung imaging performance.

**Laboratory results of COVID-19 patients (table 3)**

Leukopenia accounted for 22.6% (25.7% vs 20.2%), lymphocytopenia 47.6% (48.6% vs 46.8%), anemia 24.4% (20.3% vs 27.7%), thrombocytopenia 14.3% (16.2% vs 12.8%), but there was no significant difference between the two groups at admission.

The Prothrombin Time (PT) in imported patients (median 12.1s) was longer than local patients (median 11.7s). Also, the proportion of increased D-dimer in imported patients was significantly higher (0.35 mg/L vs 0.26 mg/L), $p<0.1$.

The results of blood gas analysis in the two groups were similar. Alkalosis was present in 68.6% of the patients, while 28.3% of the patients had a decrease in PaO2 and 37.1% had a decrease in PaCO2. No significant difference was found.

Most patients had hypoalbuminemia (56.2%), of which the albumin level of imported patients (median 37.87g/L, 62.2%) is lower than that of local patients (median 39.64g/L, 51.6%), but there are no significant difference. The prevalence of abnormal serum ALT was 11.8% and AST was 10.7%, while that of CK and CK-MB was less than 10%, but there was still no significant difference.

There was a significant difference in hyponatremia 25.7% VS 11.6% ($p=0.025$). The median serum potassium and median serum sodium of imported patients (3.95mmol/L and 137.0mmol/L respectively)
were significantly lower than those of local patients (4.15mmol/L and 137.8mmol/L), while the proportion of hyperglycemia was significantly higher than that of local patients (50% vs 34%, \( p<0.1 \)).

In addition, C-reactive protein (CRP) was elevated in more than half of the patients (58.1% vs 50.5%). The median CRP of imported patients was 12.71mg/L, while the median CRP of local patients was 9.92mg/L, but there was no statistical difference. Surprisingly, only three patients had increased procalcitonin.

**Complications, treatments and clinical outcomes of COVID-19 patients (table 4)**

The moderate type of COVID-19 was the most common (70.3% vs 82.1%), followed by severe, mild, and the critical type. The proportion of severe type of imported patients (20.3%) was significantly higher than that of local patients (9.3%), while the proportion of moderate type was significantly lower (70.3% vs 81.4%), \( p<0.1 \).

During hospitalization, 18 patients had severe complications, such as acute respiratory distress syndrome (ARDS), shock, acute kidney injury (AKI), and multiple organ dysfunction syndrome (MODS). The incidence of ARDS in imported patients (12.2%) was higher than that in local patients (7.4%). Shock only occurred in imported patients (2.7%). Twenty patients were admitted to the ICU, of which 13.5% were imported patients and 10.5% were local patients. Oxygen therapy was administered in about 95% of patients in both groups. There were two patients treated with ECMO and one patient was treated with continuous renal replacement therapy, all were imported patients. No statistical difference was observed.

All patients received antiviral therapy during hospitalization, with about 25% receiving monotherapy and 75% receiving combination therapy. The most used antiviral drugs were Lopinavir/Ritonavir, interferon and Arbidol. The patients received monotherapy were using Lopinavir/Ritonavir or Arbidol, and the patients received combination therapy were using Lopinavir/Ritonavir and Arbidol or interferon. The proportion of monotherapy or combination therapy between two groups don’t have significantly difference.

The use of antibiotics, glucocorticoids, and gamma globulins was significantly higher in the imported patients than in local patients (60.8% vs 44.2%, 36.5% vs 17.9%, 36.5% vs 17.9%, respectively), \( p<0.05 \). The antibiotics included Moxifloxacin, Cefoperazone, Piperacillin, and Meropenem.

The type of glucocorticoid was methylprednisolone, with the usual initial dose of 40mg, and the maximum dose of 80mg. The dose of gamma globulin was calculated by 0.25g per kilogram. Glucocorticoids and gamma globulins were not used unless a panel discussion by experts considered them necessary (e.g., ARDS). The median course of treatment of the glucocorticoid was 7-days, while the median course of gamma globulins was 6-days. The median viral clearance duration in imported patients was significantly longer than that in local patients (11 days vs 9 days, \( p=0.080 \)).

As of March 2\(^{nd}\), 2020, a total of 154 patients were discharged, one died (imported case), and 14 (1 imported case and 13 local patients) were still in hospital. Since Wuhan was closed on 23\(^{rd}\) January,
there were no more imported patients after the 5\textsuperscript{th} of February, therefore, the patients admitted to the hospital at the later stages were local patients. The median length of hospital stay was 13-days.

**Discussion**

This is a retrospective study to explore whether there is a difference between imported cases and local cases of COVID-19. We included 169 patients from Changsha and Xiangtan and divided them into imported patients and local patients according to their epidemiological history. Most patients had a mild fever during the disease. There were higher proportions of fever and abnormal pulmonary auscultation in imported patients.

The clinical classification of mild, moderate, severe, and critical were used. The proportion of the severe type in imported patients was higher, while the proportion of moderate type was lower, indicating that imported patients had more severe clinical manifestations than local patients. In terms of laboratory tests, in imported patients, the proportions of hypokalemia, hyponatremia, prolonged PT, elevated D-dimer and blood glucose were higher, which may be related to the more serious disturbances of the internal environment caused by the infection. In addition, there were higher proportions of hypoproteinemia, lymphocytopenia, elevated CRP, and elevated LDH in imported patients, without significant difference, which are the most common clinical biochemical abnormalities found in COVID-19 pneumonia [7]. These findings demonstrate that imported patients are more likely to progress to the severe type of COVID-19.

Another finding in this study was that more antibiotics were used in imported patients. The most common antibiotic used was moxifloxacin, which is a broad-spectrum antibiotic, suggesting that the imported patients may have a higher rate of superimposed bacterial infections compared to local patients. In addition, the proportions of using glucocorticoids and gamma globulins in imported patients were also higher, suggesting that the infection and incidence of inflammatory storms is more serious in imported patients.

In this study, the viral clearance duration was longer in imported patients. The median viral clearance duration was 11-days in imported patients and 9-days in local patients, which was close to that of Chen et al [13]. Chen et al found that the viral clearance duration in patients admitted into ICU was longer than those not admitted into ICU. In other words, the median viral clearance duration may take longer in the more severe cases. We speculate that the negative nucleic acid tests may be related to the viral load of patients, Dr. Liu and his colleagues have identified that the viral load is positively correlated to the clinical manifestations and biochemical indicators in patients [14], which may explain to some extent why imported patients are more serious than local patients.

Compared with the study in Wuhan [15], the mortality of COVID-19 pneumonia patients in Hunan was 0.5%, the proportion of severe and critical types were 16.9%, which conform with the data of other provinces out of Hubei [5, 6], but was significantly lower than that in Wuhan. There are a lot of factors that play important roles for the high mortality in Wuhan. The outbreak of COVID-19 pneumonia in Hubei
where medical resources were relatively scarce, meant mild patients could not be admitted to hospital, which led to the much higher proportion of severe patients. Based on our study, where medical resources were available for all still found that the clinical manifestations and the ratio requiring special treatment was higher in the imported patients compared with local patients.

A recent study has shown that the incubation period of SARS-CoV-2 in tertiary patients is longer than that in primary and secondary patients, and the viral load is lower, so the infectivity of SARS-CoV-2 in tertiary patients may gradually decrease [16]. This study also mentioned that there were no significant differences in early clinical signs and symptoms between primary, secondary, and tertiary patients, which are consistent with the results of our current study. Another study presented a linear correlation between viral load and severity of lung injury [14]. Therefore, we speculate that the virulence of SARS-CoV-2 may have decreased during the infection of local patients. The clinical characteristics of imported and local patients are not significantly different in the early stages, but as the disease progresses, the imported patients tended to develop more serious symptoms than local patients, indicating that closer observation and earlier intervention for the imported cases may be required.

Psychological problems may be another important factor contributing to the difference between imported and local patients [17]. Lima et al. found that patients are prone to mental health problems during this epidemic, especially in Wuhan [18]. Hence, during the epidemic, all people associated with Wuhan were easily regarded as "black sheep" and suffered discrimination [19]. The imported patients in this study correlate to the local patients in Wuhan to some extent, they were more likely to suffer prejudice from the local people leading to increased psychological problems and detrimental health outcomes.

There are several limitations to our study. First, the sample size is small, which leads to limited statistical difference in some comparisons. Secondly, the mechanism of SARS-CoV-2 virulence decrease still needs further study. Thirdly, we did not have long-term follow-up that can evaluate the long-term prognosis of these patients. Finally, we only included two centers in Hunan Province, so large-scale multicenter studies are needed to verify our findings.

**Conclusions**

We found that imported COVID-19 pneumonia patients had a higher tendency to develop into the severe type of pneumonia compared with local patients and required more aggressive treatment. In view of the fact that SARS-CoV-2 has become a global epidemic [2], as there is currently limited effective medicine and treatment, it is important to pay attention to the imported population and quarantine for a while to prevent local spread. Ongoing support for medical resources in epidemic areas is paramount to prevent the collapse of the medical system in these overrun areas.

**Declarations**
Ethics approval and consent to participate: This study has been approved by the Medical Ethics Committee (Approved Number. 2020017). Given the urgent need to collect data, we abandoned this retrospective study to obtain written informed consent from patients, referring to the CIOMS guidelines.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare no conflict of interest.

Funding: This research was funded by The National Natural Science Foundation of China, grant number: 81900661.

Author Contributions: Conceptualization: Chang Wang; Lizhi Zhou and Xiangyu Chen; Data curation, Juan Chen, Yong Yang and Tianlong Huang; Formal analysis, Lizhi Zhou; Funding acquisition, Chang Wang; Supervision, Xiangyu Chen; Writing – original draft, Lizhi Zhou; Writing – review & editing, Chang Wang; Writing – revise the manuscript, Daniel M. George.

Acknowledgments: Hongzhuan Tan and Jia Zhou from Xiangya School of Public Health of Central South University provided guidance on statistical methods. Mu Li and Sydney Lipu contribute to English editing equally.

Abbreviations

COVID-19, 2019 novel coronavirus disease
SARS-CoV, severe acute respiratory syndrome-related coronavirus
SARS-CoV-2, severe acute respiratory syndrome-related coronavirus-2
CT, computed tomographic
IQR, interquartile ranges
GGO, ground-glass opacity
CK, Creatine kinase
CK-MB, Creatine kinase-MB
AKI, Acute kidney injury
MODS, Multiple organ dysfunction syndrome
ARDS, Acute respiratory distress syndrome
ICU, intensive care unit
ECMO, Extracorporeal membrane oxygenation

ALT, Alanine aminotransferase

AST, Aspartate aminotransferase

PCT, Procalcitonin

CRP, C-reactive protein

PT, Prothrombin time

LDH, Lactate dehydrogenase

APTT, Activated partial thromboplastin time

References

1. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV) [https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)]

2. Coronavirus disease 2019 (COVID-19) Situation Report–146 [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200614-covid-19-sitrep-146.pdf]

3. COVID-19 Global Pandemic Real-time Report [https://ncov.dxy.cn/ncovh5/view/pneumonia?from=dxy&source=&link=&share=]

4. CSG of the International: The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nature Microbiology 2020:1.

5. Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, Chen H, Wang D, Liu N, Liu D, et al: Characteristics of COVID-19 infection in Beijing. Journal of Infection 2020.

6. Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F: Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. Journal of Infection 2020.

7. Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DSC, et al: Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine 2020.

8. Blanquart F, Grabowski MK, Herbeck J, Nalugoda F, Serwadda D, Eller MA, Robb ML, Gray R, Kigozi G, Laeyendecker O, et al: A transmission-virulence evolutionary trade-off explains attenuation of HIV-1 in Uganda. eLife 2016, 5.

9. Chen Z, Zhang Q, Lu Y, Zhang X, Zhang W, Guo C, Liao C, Li Q, Han X, Lu J: Distribution of the 2019-nCoV Epidemic and Correlation with Population Emigration from Wuhan, China. Cold Spring Harbor Laboratory; 2020.
10. Xia W, Shao J, Guo Y, Peng X, Li Z, Hu D: Clinical and CT features in pediatric patients with COVID-19 infection: Different points from adults. Pediatric Pulmonology 2020.

11. COVID-19’s diagnosis and treatment Plan (trial version 6) [http://www.nhc.gov.cn/yzygj/s7653p/202002/8334a8326dd94d329df351d7da8ae6c2.shtml]

12. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, Xu W, Zhang C, Yu J, Jiang B, et al: Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clinical Infectious Diseases 2020.

13. Chen J, Qi T, Liu L, Ling Y, Qian Z, Li T, Li F, Xu Q, Zhang Y, Xu S, et al: Clinical progression of patients with COVID-19 in Shanghai, China. Journal of Infection 2020.

14. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, et al: Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences 2020, 63:364-374.

15. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020.

16. Xu T, Chen C, Zhu Z, Cui M, Chen C, Dai H, Xue Y: Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. International Journal of Infectious Diseases 2020.

17. Kang L, Li Y, Hu S, Chen M, Yang C, Yang BX, Wang Y, Hu J, Lai J, Ma X, et al: The mental health of medical workers in Wuhan, China dealing with the 2019 novel coronavirus. The Lancet Psychiatry 2020, 7:e14.

18. Lima CKT, Carvalho PMDM, Lima IDAAS, Nunes JVADO, Saraiva JS, De Souza RI, Da Silva CGL, Neto MLR: The emotional impact of Coronavirus 2019-nCoV (new Coronavirus disease). Psychiatry Research 2020, 287:112915.

19. Ren S-Y, Gao R-D, Chen Y-L: Fear can be more harmful than the severe acute respiratory syndrome coronavirus 2 in controlling the coronavirus disease 2019 epidemic. World Journal of Clinical Cases 2020, 8:652.

Tables

Table 1. Demographics, baseline and clinical characteristics of COVID-19 pneumonia patients.
| Variables                                      | All cases (n=169) | imported cases (n=74) | local cases (n=95) | P Value |
|------------------------------------------------|-------------------|-----------------------|-------------------|---------|
| **Age (yr)**                                   |                   |                       |                   |         |
| Median (IQR)                                   | 45 (34.5-55)      | 45 (35-53.5)          | 43 (34-57)        | 0.872   |
| Range                                          |                   |                       |                   |         |
| 19-49                                         | 106 (62.7)        | 50 (67.6)             | 56 (58.9)         | 0.392   |
| 50-64                                         | 38 (22.5)         | 13 (17.6)             | 25 (26.3)         |         |
| ≥65                                           | 25 (14.8)         | 11 (14.9)             | 14 (14.7)         |         |
| **Sex**                                        |                   |                       |                   |         |
| Male                                           | 86 (50.9)         | 40 (54.1)             | 46 (48.4)         | 0.536   |
| Female                                         | 83 (49.1)         | 34 (45.9)             | 49 (51.6)         |         |
| **Temperature on admission (°C)**              |                   |                       |                   |         |
| Median (IQR)                                   | 36.8 (36.5-37.4)  | 37.0 (36.6-37.5)      | 36.8 (36.5-37.2)  | 0.076   |
| Range                                          |                   |                       |                   |         |
| <37.3                                         | 120 (71.0)        | 46 (62.1)             | 74 (77.9)         | 0.065   |
| 37.3-38.0                                      | 37 (21.9)         | 21 (28.4)             | 16 (16.8)         |         |
| 38.1-39.0                                      | 11 (6.5)          | 7 (9.5)               | 4 (4.2)           |         |
| ≥39                                           | 1 (0.6)           | 0 (0)                 | 1 (1.1)           |         |
| **Pulmonary auscultation on admission**        |                   |                       |                   |         |
| Crackles                                       | 9 (5.3)           | 5 (6.8)               | 4 (4.2)           | 0.507   |
| Stridor                                        | 0 (0)             | 0(0)                  | 0 (0)             | 1.000   |
| Both                                           | 3 (1.8)           | 3 (4.1)               | 0 (0)             | 0.082   |
| **Complication**                               |                   |                       |                   |         |
| Not less than 1                                | 53 (31.4)         | 19 (25.7)             | 34 (35.8)         | 0.183   |
| Recurrent respiratory infections               | 4 (2.4)           | 1 (1.4)               | 3 (3.2)           | 0.632   |
| Hypertension                                   | 19 (11.2)         | 6 (8.1)               | 13 (13.7)         | 0.329   |
| Diabetes                                       | 13 (7.7)          | 4 (5.4)               | 9 (9.5)           | 0.393   |
| Immunodeficiency                               | 2 (1.2)           | 0 (0)                 | 2 (2.1)           | 0.505   |
| Chronic obstructive pulmonary disease          | 3 (1.8)           | 1 (1.4)               | 2 (2.1)           | 1.000   |
| Cancer                                         | 2 (1.2)           | 1 (1.4)               | 1 (1.1)           | 1.000   |
| Cardiovascular and cerebrovascular diseases    | 10 (5.9)          | 2 (2.7)               | 8 (8.4)           | 0.189   |
| **Symptoms or signs**                          |                   |                       |                   |         |
| Fever                                          | 123 (72.8)        | 58 (78.4)             | 65 (68.4)         | 0.167   |
| Cough                                          | 136 (80.5)        | 64 (86.5)             | 72 (75.8)         | 0.117   |
| Expectoration                                  | 71 (42.0)         | 28 (37.8)             | 43 (45.3)         | 0.350   |
| Hemoptysis                                     | 4 (2.4)           | 3 (4.1)               | 1 (1.1)           | 0.320   |
| Nasal congestion                               | 3 (1.8)           | 1 (1.4)               | 2 (2.1)           | 1.000   |
| Headache                                       | 23 (13.6)         | 7 (9.5)               | 16 (16.8)         | 0.183   |
| Shortness of breath                            | 37 (21.9)         | 20 (27.0)             | 17 (17.9)         | 0.190   |
| Muscle soreness                                | 11 (6.5)          | 3 (4.1)               | 8 (8.4)           | 0.351   |
| Fatigue                                        | 73 (43.2)         | 32 (43.2)             | 41 (43.2)         | 1.000   |
| Gastrointestinal symptoms                      | 53 (31.4)         | 22 (29.7)             | 31 (32.6)         | 0.740   |
| **Onset-visit interval(days)**                 |                   |                       |                   |         |
| Median (IQR)                                   | 3 (1-6)           | 3 (1-6)               | 3 (1-6)           | 0.711   |

Data are n (%) or median (IQR), unless otherwise specified.
Table 2. Radiographic findings of COVID-19 patients.

| Variables                        | All cases (n=169) | Imported cases (n=74) | Local cases (n=95) | P Value |
|----------------------------------|-------------------|-----------------------|--------------------|---------|
| **CT findings on admission**     |                   |                       |                    |         |
| Ground-glass opacity (GGO) only  | 130/166 (78.3)    | 57/73 (78.1)          | 73/93 (78.5)       | 1.000   |
| Consolidation only               | 1/166 (0.6)       | 0/73 (0)              | 1/93 (1.1)         | 1.000   |
| Mixed GGO and consolidation      | 21/166 (12.7)     | 10/73 (13.7)          | 11/93 (11.8)       | 0.815   |
| **Involved scope**               |                   |                       |                    |         |
| Unilateral pneumonia             | 19/166 (11.4)     | 6/73 (8.2)            | 13/93 (14.0)       | 0.328   |
| Bilateral pneumonia              | 136/166 (81.9)    | 62/73 (84.9)          | 74/93 (79.6)       | 0.421   |
| **CT findings after treatment**  |                   |                       |                    |         |
| Ground-glass opacity (GGO) only  | 81/163 (49.7)     | 39/72 (54.2)          | 42/91 (46.2)       | 0.346   |
| Consolidation only               | 1/163 (0.6)       | 0/72 (0)              | 1/91 (1.1)         | 1.000   |
| Mixed GGO and consolidation      | 53/163 (32.5)     | 21/72 (29.2)          | 32/91 (35.2)       | 0.501   |

Data are n (%), n/N (%) or median (IQR), unless otherwise specified.

Data were missing for the item in several cases.

Table 3. Laboratory results of COVID-19 patients.
| Variables               | Normal range | All cases (n=169) | imported cases (n=74) | local cases (n=95) | P Value |
|-------------------------|--------------|-------------------|-----------------------|--------------------|---------|
| **Blood routine**       |              |                   |                       |                    |         |
| Leucocytes\(^1\) (×10\(^9\)/L) | 3.5-9.5      | 4.62 (3.63-5.89)  | 4.61 (3.44-5.99)      | 4.62 (3.64-5.87)   | 0.844   |
| Increased               | 4/168 (2.4)  | 1 (1.4)           | 3/94 (3.2)            | 0.631              |
| Decreased               | 38/168 (22.6)| 19 (25.7)         | 19/94 (20.2)          | 0.459              |
| Neutrophils\(^1\) (×10\(^9\)/L) | 1.8-6.3      | 2.89 (2.30-3.67)  | 2.80 (2.26-3.56)      | 2.93 (2.30-3.77)   | 0.693   |
| Increased               | 9/168 (5.4)  | 4 (5.4)           | 5/94 (5.3)            | 1.000              |
| Decreased               | 17/168 (10.1)| 6 (8.1)           | 11/94 (11.7)          | 0.608              |
| Lymphocytes\(^1\) (×10\(^9\)/L) | 1.1-3.2      | 1.13 (0.81-1.55)  | 1.11 (0.81-1.53)      | 1.18 (0.81-1.60)   | 0.666   |
| Increased               | 2/168 (1.2)  | 0 (0)             | 2/94 (2.1)            | 0.504              |
| Decreased               | 80/168 (47.6)| 36 (48.6)         | 44/94 (46.8)          | 0.877              |
| Hemoglobin\(^1\) (g/L)  | 120-160      | 130.5 (120.0-141.8)| 132.0 (121.0-143.0)  | 129.0 (117.8-141.0)| 0.150   |
| Decreased               | 41/168 (24.4)| 15 (20.3)         | 26/94 (27.7)          | 0.284              |
| Platelets\(^1\) (×10\(^9\)/L) | 125-350      | 175.5 (145.0-227.0)| 172.5 (139.0-228.0)  | 181.5 (145.8-227.3)| 0.699   |
| Increased               | 3/168 (1.8)  | 1 (1.4)           | 2/94 (2.1)            | 1.000              |
| Decreased               | 24/168 (14.3)| 12 (16.2)         | 12/94 (12.8)          | 0.658              |
| **Coagulation Function**|              |                   |                       |                    |         |
| Prothrombin time\(^1\) (s) | 9.4-12.5     | 11.8 (11.0-12.7)  | 12.1 (11.2-12.7)      | 11.7 (10.8-12.5)   | 0.099   |
| Increased               | 44/167 (26.3)| 22 (29.7)         | 22/93 (23.7)          | 0.384              |
| Activated partial thromboplastin time\(^1\) (s) | 25.1-36.5 | 33.1 (30.4-36.1)  | 32.9 (31.0-35.6)      | 33.3 (30.2-36.8)   | 0.943   |
| Increased               | 40/167 (24.0)| 15 (20.3)         | 25/93 (26.9)          | 0.364              |
| Decreased               | 5/167 (3.0)  | 0 (0)             | 5/93 (5.4)            | 0.067              |
| D-dimer\(^1\) (mg/L)    | 0.0-0.5      | 0.31 (0.15-0.57)  | 0.36 (0.19-0.59)      | 0.26 (0.13-0.53)   | 0.072   |
| Increased               | 50/167 (29.9)| 26 (35.1)         | 24/93 (25.8)          | 0.234              |
| **Blood gas analysis**  |              |                   |                       |                    |         |
| pH\(^1\)                | 7.35-7.45    | 7.47 (7.45-7.50)  | 7.47 (7.44-7.51)      | 7.48 (7.45-7.50)   | 0.785   |
| Increased               | 109/159 (68.6)| 45/70 (64.3)      | 64/89 (71.9)          | 0.309              |
| Decreased               | 1/159 (0.6)  | 0/70 (0)          | 1/89 (1.1)            | 1.000              |
| PaO\(_2\)\(^1\) (mmHg)  | 75-105       | 87.4 (71.6-109.0) | 90.7 (70.8-109.4)     | 86.0 (72.0-108.4)  | 0.429   |
| Decreased               | 45/159 (28.3)| 19/70 (27.1)      | 26/89 (29.2)          | 0.860              |
| PaCO\(_2\)\(^1\) (mmHg) | 35-46        | 37.0 (32.9-40.6)  | 36.6 (33.6-39.7)      | 37.5 (32.8-41.3)   | 0.718   |
| Increased               | 8/159 (5.0)  | 4/70 (5.7)        | 4/89 (4.5)            | 0.732              |
| Decreased               | 59/159 (37.1)| 26/70 (37.1)      | 33/89 (37.1)          | 1.000              |
| **Blood biochemistry**  |              |                   |                       |                    |         |
| Albumin (g/L)           | 40.0-55.0    | 38.8 (35.6-42.7)  | 37.87 (35.43-42.36)   | 39.64 (36.30-43.30)| 0.133   |
| Decreased               | 95 (56.2)    | 46 (62.2)         | 49 (51.6)             | 0.211              |
| Alanine aminotransferase (U/L) | 9-50        | 19.9 (13.9-29.3)  | 20.9 (13.6-30.5)      | 19.7 (14.0-28.3)   | 0.611   |
| Increased               | 18 (10.7)    | 10 (13.5)         | 8 (8.4)               | 0.322              |
| Aspartate aminotransferase (U/L) | 15-40    | 22.5 (17.3-28.6)  | 23.2 (16.0-29.1)      | 21.9 (17.5-28.2)   | 0.837   |
| Test                                    | Median (IQR)               | Increased          | 10 (13.5) | 10 (10.5) | 0.634 |
|-----------------------------------------|----------------------------|--------------------|-----------|-----------|-------|
| Creatine kinase (U/L)                   | 68.5 (40.9-103.9)          | 17 (10.1)          | 9 (12.2)  | 8 (8.4)   | 0.450 |
| Creatine kinase-MB (U/L)                | 9.8 (6.3-12.3)             | 10 (5.9)           | 4 (5.4)   | 6 (6.3)   | 1.000 |
| Total bilirubin (μmol/L)                | 171 (68.5-103.9)           | 72.0 (39.9-108.6)  | 65.0 (41.0-90.5) | 0.712 |
| Serum potassium (mmol/L)                | 4.10 (3.69-4.44)           | 3.95 (3.63-4.40)   | 4.15 (3.85-4.48) | 0.058 |
| Total bilirubin (μmol/L)                | 137.5 (135.6-139.8)        | 137.0 (134.8-139.8)| 137.8 (136.1-139.9) | 0.088 |
| Serum sodium (mmol/L)                   | 4.26 (3.42-5.30)           | 4.38 (3.36-5.33)   | 4.13 (3.45-5.30) | 0.560 |
| Lactate dehydrogenase (U/L)             | 169.0 (140.1-216.1)        | 176.6 (137.7-226.8)| 160.1 (141.4-207.5) | 0.264 |
| Glucose (mmol/L)                        | 5.63 (4.95-7.44)           | 6.10 (5.07-7.75)   | 5.41 (4.86-6.95)  | 0.049 |

**Table 4. Complications, treatments and clinical outcomes of COVID-19 patients.**
| Variables                        | All cases (n=169) | imported cases (n=74) | local cases (n=95) | P Value |
|---------------------------------|-------------------|-----------------------|--------------------|---------|
| **Clinical classification**     |                   |                       |                    |         |
| Mild type                       | 10 (5.9)          | 5 (6.8)               | 5 (5.3)            | 0.750   |
| Moderate type                   | 130 (76.9)        | 52 (70.3)             | 78 (82.1)          | 0.097   |
| Severe type                     | 24 (14.2)         | 15 (20.3)             | 9 (9.5)            | 0.074   |
| Critical type                   | 5 (3.0)           | 2 (2.7)               | 3 (3.2)            | 1.000   |
| **Severe complication**         |                   |                       |                    |         |
| ARDS                            | 16 (9.5)          | 9 (12.2)              | 7 (7.4)            | 0.304   |
| Shock                           | 2 (1.2)           | 2 (2.7)               | 0 (0)              | 0.190   |
| AKI                             | 4 (2.4)           | 1 (1.4)               | 3 (3.2)            | 0.632   |
| MODS                            | 3 (1.8)           | 1 (1.4)               | 2 (2.1)            | 1.000   |
| **Treatments**                  |                   |                       |                    |         |
| Admitted in ICU                 | 20 (11.8)         | 10 (13.5)             | 10 (10.5)          | 0.634   |
| Oxygen therapy                  | 162 (95.9)        | 71 (95.9)             | 91 (95.8)          | 1.000   |
| High-flow nasal cannula oxygen therapy | 14 (8.3) | 7 (9.5) | 7 (7.4) | 0.780   |
| Prone Positioning               | 4 (2.4)           | 2 (2.7)               | 2 (2.1)            | 1.000   |
| non-invasive positive pressure ventilation | 7 (4.1) | 3 (4.1) | 4 (4.2) | 1.000   |
| Invasive positive pressure ventilation | 3 (1.8) | 2 (2.7) | 1 (1.1) | 0.582   |
| Extracorporeal membrane oxygenation | 2 (1.2) | 2 (2.7) | 0 (0) | 0.190   |
| Continuous renal replacement therapy | 1 (0.6) | 1 (1.4) | 0 (0) | 0.438   |
| **Antiviral treatment**         |                   |                       |                    |         |
| Monotherapy                     | 41 (24.3)         | 16 (21.6)             | 25 (26.3)          | 0.588   |
| Combination therapy             | 128 (75.7)        | 58 (78.4)             | 70 (73.7)          | 0.588   |
| **Antibiotic treatment**        |                   |                       |                    |         |
| Glucocorticoids                 | 44 (26.0)         | 27 (36.5)             | 17 (17.9)          | 0.008   |
| Course of treatment (days) -Median (IQR) | 7 (5-9) | 7 (5-10) | 6 (4-8.5) | 0.259   |
| Gamma globulin                  | 44 (26.0)         | 27 (36.5)             | 17 (17.9)          | 0.008   |
| Course of treatment (days) -Median (IQR) | 6 (4-8) | 6 (4-7) | 6 (3.5-8.5) | 0.913   |
| **Clinical outcome**            |                   |                       |                    |         |
| Discharged from hospital        | 154 (91.1)        | 72 (97.3)             | 82 (86.3)          | 0.002   |
| Death                           | 1 (0.6)           | 1 (1.4)               | 0 (0)              |         |
| Hospitalization                 | 14 (8.3)          | 1 (1.4)               | 13 (13.7)          |         |
| Length of hospital stay (days)  | 13 (11.0-18.0)    | 13 (11.0-17.8)        | 13 (10.0-19.0)     | 0.916   |
| **Viral clearance duration (days)** |                  |                       |                    | 0.080   |
| Median (IQR)                    | 10 (8-15)         | 11 (8-15)             | 9 (7-15)           |         |

Data are n (%), or median (IQR), unless otherwise specified.

1 patients without symptoms before onset were exclude.